Saturday, October 3, 2026

Nano Dimension Stock Went Down By Over 13% At Session Start Today

Nano Dimension Stock Went Down By Over 13% At Session Start Today

(VIANEWS) - Shares of Nano Dimension (NASDAQ: NNDM) dropped by a staggering 13.22% to $2.69 at 10:16 EST on Friday, following the last session's upward trend. NASDAQ is falling 2.05% to $11,338.35, following the last session's downward trend. This seems, at the moment, an all-around down trend exchanging session today.

Nano Dimension's last close was $3.10, 22.11% below its 52-week high of $3.98.

About Nano Dimension

Nano Dimension Ltd., together with its subsidiaries, provides additive electronics in Israel and internationally. The company's flagship product is DragonFly IV system that serves cross-industry High-Performance-Electronic-Devices' fabrication needs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components. It also provides nanotechnology based conductive and dielectric inks; and FLIGHT software platform that enables the 3D design of electrical and mechanical features. The company markets and sells products and services to companies that develop products with electronic components, including companies in the defense, automotive, consumer electronics, semiconductor, aerospace, and medical industries, as well as research institutes. Nano Dimension Ltd. was founded in 2012 and is headquartered in Ness Ziona, Israel.

Earnings Per Share

As for profitability, Nano Dimension has a trailing twelve months EPS of $-1.129.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -22.01%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nano Dimension's stock is considered to be oversold (<=20).

More news about Nano Dimension (NNDM).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com